|
Bunevicius, et al 1999[7] |
Bunevicius 2002[32] |
Clyde, et al 2003[28] |
Sawka, et al 2003[29] |
Walsh, et al 2003[31] |
Siegmund, et al 2004[30] |
Rodriguez, et al 2005[33] |
Escobar-Morreale 2005[34] |
Saravanan 2005[35] |
Number of study participants (n)/cohort |
33 |
10 |
46 |
40 |
110 |
23 |
27 |
28 |
697 |
|
Patients with chronic autoimmune thyroiditis or thyroid cancer treated by near-total thyroidectomy |
Women with sub-total thyroid-ectomy for Graves' disease |
Ages 24–65 with primary hypothyroidism |
Patients with depressive symptoms and primary hypothyroidism |
85% autoimmune or idiopathic hypothyroidism. Remaining had post-surgical hypo-thyroidism,Graves' disease, and Hashimoto's disease. |
Hypothyroidism due to surgery/radioiodine (21) or auto-immune thyroiditis (2) |
Primary hypothyroidism |
Women with overt primary hypothyroidism |
Family practice patients 18–75 with T4 dose > 100 mcg/day and no T4 adjustments in the past 3 months. Thyroid CA and Secondary Hypothyroidism excluded. |
Study design |
Randomized control, crossover-design |
Double blind, cross-over study |
Randomized control trial |
Randomized control trial |
Double blind, randomized control trial with cross-over Design |
Double blind, randomized control trial with cross-over design |
Double blind, randomized control trial with cross-over design |
Double blind, randomized cross-over trial |
Double blind, randomized cross-over trial |
Treatment |
Original T4 dosage at baseline vs original dosage minus 50 mcg T4 replaced by 12.5 mcg of T3 per day. |
Original T4 dosage at baseline vs original dosage minus 50 mcg T4 replaced by 10 mcg T3 per day. |
Original T4 dosage at baseline vs original dosage minus 50 mcg T4 replaced with 7.5 mcg T3 given twice a day. |
Original T4 dose at baseline vs half of original T4 dosage plus 12.5 mcg of T3 twice a day. |
Original T4 dosage vs original dose minus 50 mcg T4 plus 10 mcg T3 once a day. |
Original T4 dosage vs original does minus 5% T4 replaced by T3 in that amount once a day. |
Original T4 dosage vs original dose minus 50 mcg T4 replaced by 10 mcg T3 once a day. |
100 mcg T4e vs 75 mcg T4 plus 5 mcg T3. All pts received 87.5 mcg thyroxine plus 7.5 mcg T3 per day during the last 8 weeks. |
Original T4 dosage vs original dose minus 50 mcg T4 plus 10 mcg T3 per day. |
Length of study periods (in weeks) |
5 |
5 |
16 |
15 |
10 |
12 |
6 |
8 |
12 |
Improved condition from combination therapy |
Significant improvement in 2/8 cognitive tests; 4/9 mood scores; 4/8 mood reports; 3/7 physical symptoms. |
Symptoms tended to decrease after combined treatment. Mental state tended to improve with combined treatment, cognitive tests did not improve. |
No changes measured by HRQL questionnaire and standard measures of cognitive performance. |
No changes detected by all subscalres of the Symptom Check List-90, the Comprehensive Epidemiological Screen for Depression, and the Multiple Outcome Study. |
No changes in cognitive function, quality of life scores, Thyroid Symptom Questionaire scores, subjective satisfaction with treatment, or 8 of 10 visual analog scales. |
No improvement in mood scores, cognitive performance vs T4 monotherapy. |
No changes in measures of fatigue, symptoms of depression, or working memory. |
No objective advantage was identified with the combination treatment; however, subjective tests found a significant preference of patients for the combination treatment. |
Possibly a subgroup of patients showing transient improvement with combined Rx/No conclusive evidence of specific benefits. Large, sustained placebo effect also seen. |
Comments